Aberrant CYP2D6 metabolizer phenotypes do not show increased frequency in patients undergoing ECT after antidepressant therapy.

Mirzakhani, Hooman; van Dormolen, Juliët; van der Weide, Karen; Guchelaar, Henk-Jan; van Noorden, Martijn S; Swen, Jesse

Mirzakhani, Hooman; van Dormolen, Juliët; van der Weide, Karen; Guchelaar, Henk-Jan; van Noorden, Martijn S; Swen, Jesse.

Afiliação

Mirzakhani H; aDepartment of Medicine, Channing Division of Network Medicine, Brigham and Women's Hospital bDepartment of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA cDepartment of Clinical Pharmacy & Toxicology dDepartment of Psychiatry, Leiden University Medical Center, Leiden University, Leiden, The Netherlands eDepartment of Clinical Chemistry, St Jansdal Hospital, Harderwijk, The Netherlands.

Pharmacogenet Genomics ; 25(10): 515-7, 2015 Oct.

Article em En | MEDLINE | ID: mdl-26230381

Assuntos

Antidepressivos/uso terapêutico; Citocromo P-450 CYP2D6/metabolismo; Eletroconvulsoterapia; Idoso; Idoso de 80 Anos ou mais; Feminino; Humanos; Modelos Logísticos; Masculino; Pessoa de Meia-Idade; Análise Multivariada; Fenótipo

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Citocromo P-450 CYP2D6 / Eletroconvulsoterapia / Antidepressivos Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google